In recent years, with the emergence of microbial resistance and pathogen mutations in the world, the in vitro diagnosis of infectious diseases has become one of the hot spots for major pharmaceutical technology companies. Whenever there is a new type of infectious disease or a new type of screening method, the market for disease test and diagnosis will always be resurrected and a new R&D feast will be opened. At present, laboratory diagnostic techniques for infectious diseases usually include PCR amplification, gene sequencing, microarrays, and mass spectrometry. As communicable diseases are increasingly prevalent and testing needs are on the rise, it is expected that by 2020, the communicable disease detection market will increase from US$16.8 billion in 2015 to US$20.9 billion. The clinical needs of infectious disease test are still relatively large gap, laboratory tests are still mainly based on the traditional pathogen identification - drug sensitivity test procedures, supplemented by routine immunoassay testing. For major outbreaks or pathogens that are difficult to cultivate in vitro, molecular diagnostic methods are used for screening. Molecular diagnosis mainly refers to the use of various biotechnologies for the detection of individual DNA or RNA in tissues to diagnose diseases, monitor treatment, or judge prognosis.